Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Receivables - Other (2019 - 2025)

Historic Receivables - Other for Bicycle Therapeutics (BCYC) over the last 7 years, with Q3 2025 value amounting to $67.3 million.

  • Bicycle Therapeutics' Receivables - Other rose 1603.45% to $67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.3 million, marking a year-over-year increase of 1603.45%. This contributed to the annual value of $35.7 million for FY2024, which is 4831.32% up from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Receivables - Other is $67.3 million, which was up 1603.45% from $60.8 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Receivables - Other peaked at $67.3 million during Q3 2025, and registered a low of $7.7 million during Q3 2021.
  • In the last 5 years, Bicycle Therapeutics' Receivables - Other had a median value of $24.0 million in 2023 and averaged $30.4 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 2081.13% in 2023, then soared by 26047.04% in 2024.
  • Over the past 5 years, Bicycle Therapeutics' Receivables - Other (Quarter) stood at $7.7 million in 2021, then soared by 148.73% to $19.2 million in 2022, then grew by 25.45% to $24.0 million in 2023, then skyrocketed by 48.31% to $35.7 million in 2024, then soared by 88.76% to $67.3 million in 2025.
  • Its Receivables - Other stands at $67.3 million for Q3 2025, versus $60.8 million for Q2 2025 and $46.2 million for Q1 2025.